Local pharmaceutical companies will face the full range of multinational pharmaceutical companies siege - are you ready-.docVIP

 PAGE \* MERGEFORMAT 12 Local pharmaceutical companies will face the full range of multinational pharmaceutical companies siege - are you ready? Multinational pharmaceutical companies into China since the beginning of exploratory into line with a considerable degree of control over the market, and now they have figured out the current round of health reform policy in China, began marching to the local primary market. Pfizer, Merck, GlaxoSmithKline, Novartis, Sanofi, Nycomed and other multinational pharmaceutical giants, the recent increase China M amp; A, joint venture initiatives. Multinational pharmaceutical companies into China since the beginning of exploratory into line with a considerable degree of control over the market, and now they have figured out the current round of health reform policy in China, began marching to the local primary market. Pfizer, Merck, GlaxoSmithKline, Novartis, Sanofi, Nycomed and other multinational pharmaceutical giants, the recent increase China M amp; A, joint venture initiatives. ‘We are well aware of China’s medical reform, China’s second Five-Year plan, China is also well aware of industry problems?’ In mid-August, Merck collaboration with Simcere media conference, Merck Sharp amp; Dohme (China) Limited President Wonner Yuxi said. After the meeting, Wonner Yuxi said: ‘We have the Chinese medical reform policy has been very careful study, last month, we have just completed the second Five-Year Plan of China.’ Articles in recent interview that, at this stage, most multinational pharmaceutical companies in China, such as Merck general self-confidence. Multinational pharmaceutical companies into China these years, from the tentative into line with a considerable degree of control over the market, now the multinational pharmaceutical companies have figured out the current round of health reform policy in China, began marching to the local primary market. Perhaps, from multinational pharmaceutical companies invest